|
METTL2B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.63779944740395E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.75539998887353E-09 |
| Normal-vs-Stage2 |
3.396300E-03 |
| Normal-vs-Stage3 |
9.63830004696575E-09 |
| Normal-vs-Stage4 |
6.5626000000929E-07 |
| Stage1-vs-Stage2 |
1.772840E-01 |
| Stage1-vs-Stage3 |
1.907800E-01 |
| Stage1-vs-Stage4 |
2.304000E-01 |
| Stage2-vs-Stage3 |
4.844200E-02 |
| Stage2-vs-Stage4 |
7.311800E-02 |
| Stage3-vs-Stage4 |
8.538400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.01259994728298E-09 |
| Normal-vs-AfricanAmerican |
3.551500E-04 |
| Normal-vs-Asian |
8.161800E-04 |
| Caucasian-vs-AfricanAmerican |
9.622600E-01 |
| Caucasian-vs-Asian |
2.889800E-01 |
| AfricanAmerican-vs-Asian |
5.175200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.50479970098638E-10 |
| Normal-vs-Female |
2.90249999590486E-08 |
| Male-vs-Female |
2.584400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.75009999720177E-08 |
| Normal-vs-Age(41-60Yrs) |
1.66970000048394E-08 |
| Normal-vs-Age(61-80Yrs) |
5.1415000001942E-07 |
| Normal-vs-Age(81-100Yrs) |
5.696200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.269800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.031600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.398000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.070200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.704000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.216600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.446300E-02 |
| Classical-VS-Follicular |
1.068050E-01 |
| Classical-VS-Other |
1.109770E-01 |
| Classical-VS-Normal |
9.5773999952975E-08 |
| Tall-VS-Follicular |
5.512000E-01 |
| Tall-VS-Other |
4.775400E-01 |
| Tall-VS-Normal |
1.36719999999091E-06 |
| Follicular-VS-Other |
3.626800E-01 |
| Follicular-VS-Normal |
3.3250999997847E-07 |
| Other-VS-Normal |
1.317980E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.07990000170122E-08 |
| Normal-vs-N1 |
2.35849999999926E-05 |
| N0-vs-N1 |
7.797400E-01 |
|
|
